In the News
Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies
San Diego, CLP Magazine — In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.
Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium
New York, GenomeWeb – Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients.
Epic Sciences, Genomic Health Get Medicare LCD for Prostate Cancer Diagnostic
San Diego, Clinical OMICs – Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018.
Epic Sciences Continues Research on Multiple Fronts; Remains Quiet on Dx Development Pipeline
New York, GenomeWeb – With its first commercial diagnostic now fully launched and awaiting a final coverage decision by Medicare, Epic Sciences is keeping quiet about concrete plans for a pipeline of additional clinical assays, though it continues to collect data from research studies which may provide possibilities for future translation.
Epic Aims to ‘Revolutionize Cancer Care'
San Diego, SDBJ — Epic Sciences' pitch: greater certainty. The company's portfolio of tests guide cancer doctors deciding on a treatment path, including a test on the market for advanced prostate cancer.
Study Shows Epic Sciences Liquid Biopsy Aids Prostate Cancer Patient Selection
San Diego, Clinical OMICs – Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment.
An Epic Approach To Liquid Biopsy
San Diego, MDDI – The liquid biopsy space continues to attract investors and bring in financings that are typically above the average amount medtech firms are able to raise. Epic Sciences is the latest liquid biopsy company to obtain funding and has raised about $52 million in a series E round.